BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 708K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now
Advanced Search

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

20 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL).EBI
University of Michigan
Rational Design of Orthogonal Multipolar Interactions with Fluorine in Protein-Ligand Complexes.EBI
University of Michigan
Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface.EBI
Fuzhou University
Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.EBI
Xi'An Jiaotong University
Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression.EBI
University of Michigan
HOPPI-NMR: Hot-Peptide-Based Screening Assay for Inhibitors of Protein-Protein Interactions by NMR.EBI
University of Naples "Federico Ii
Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.EBI
TBA
Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong EBI
TBA
High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction.EBI
University of Michigan
Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction.EBI
University of Michigan
Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.EBI
University of Michigan
Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.EBI
China Pharmaceutical University
2,7-Diazaspiro[4,4]nonanes for the Treatment or Prevention of Cancers and Diabetes.EBI
Usona Institute
Piperidine Alkaloids with Diverse Skeletons from Anacyclus pyrethrum.EBI
Chinese Academy of Sciences
SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINSBDB
Taiho Pharmaceutical Co.
MACROCYCLIC 1,3-BRIDGED 6-CHLORO-7-PYRAZOL-4-YL-1 H-INDOLE-2-CARBOXYLATE AND 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE DERIVATIVES AS MCL-1 INHIBITORS FOR THE TREATMENT OF CANCERBDB
Janssen Pharmaceutica
LPA receptor antagonists and uses thereofBDB
Gilead Sciences
TYK2 inhibitors, uses, and methods for production thereofBDB
Nimbus Lakshmi
PDE9 inhibitor and use thereofBDB
Nanjing Transthera Biosciences
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor.BDB
Eli Lilly